A. Cusmai

发表

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.

F. Dammacco, M. Frassanito, A. Cusmai, 2001, Blood.

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis

F. Massari, M. Santoni, A. Ricci, 2022, Journal of personalized medicine.

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

M. C. Comes, R. Massafra, A. Zito, 2022, Cells.

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

C. Carella, L. Antonuzzo, G. Tortora, 2022, Cancers.

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

M. C. Comes, R. Massafra, A. Zito, 2022, Cancer Control : Journal of the Moffitt Cancer Center.

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

A. Cusmai, Alessandro Rizzo, G. Palmiotti, 2022, Expert opinion on investigational drugs.

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward

A. Cusmai, G. Gadaleta-Caldarola, Alessandro Rizzo, 2022, Medicina.

Management of advanced breast cancer.

M. Colleoni, A. Cusmai, L. Orlando, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined cyclosporin‐A /prednisone therapy of patients with active uveitis suppresses IFN‐γ production and the function of dendritic cells

S. Guerriero, M. Frassanito, A. Cusmai, 2003, Clinical and experimental immunology.

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

F. Dammacco, M. Frassanito, A. Cusmai, 2001, Clinical and experimental immunology.

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

V. Dadduzio, S. Infusino, A. Cusmai, 2022, Current oncology.

Advances in novel systemic therapies for advanced hepatocellular carcinoma.

R. Massafra, G. Brandi, A. Fanizzi, 2022, Future medicinal chemistry.

Blockade of the Ras pathway by manumycin, a farnesyltransferase inhibitor, overcomes the resistance of myeloma plasma cells to Fas-induced apoptosis

F. Dammacco, M. Frassanito, A. Cusmai, 2005, Clinical and Experimental Medicine.

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

S. Pignata, S. Buti, U. de Giorgi, 2022, Tumori.

G. Brandi, A. Ricci, A. Cusmai, 2022, Expert opinion on drug safety.

Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY

A. Cusmai, Alessandro Rizzo, G. Palmiotti, 2022, Expert review of gastroenterology & hepatology.

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

A. Cusmai, G. Gadaleta-Caldarola, Alessandro Rizzo, 2022, Expert review of gastroenterology & hepatology.

Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer

R. Massafra, A. Fanizzi, V. Lorusso, 2022, Expert opinion on investigational drugs.

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

E. Maiello, A. Fabi, V. Lorusso, 2017, Breast Cancer Research and Treatment.

Manumycin inhibits farnesyltransferase and induces apoptosis of drug‐resistant interleukin 6‐producing myeloma cells

F. Dammacco, C. Piccoli, M. Frassanito, 2002, British journal of haematology.

KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.

A. Cusmai, Alessandro Rizzo, G. Palmiotti, 2022, Future oncology.

721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study

C. Porta, L. Antonuzzo, G. Tortora, 2020 .

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future

G. Brandi, G. De Palma, A. Ricci, 2022, Current oncology.

Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?

G. Brandi, A. Cusmai, Alessandro Rizzo, 2022, Expert review of gastroenterology & hepatology.

Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

A. Cusmai, Alessandro Rizzo, G. Palmiotti, 2022, Cancers.

Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference.

A. Cusmai, L. Orlando, S. Cinieri, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

S. Pignata, R. Iacovelli, L. Porcu, 2021 .

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma

G. Brandi, S. Tavolari, A. Ricci, 2023, Journal of hepatocellular carcinoma.

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

C. Porta, S. Buti, M. Bersanelli, 2022, Journal of immunotherapy.